2-cyanoethylene oxide: acrylonitrile metabolite; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 20662 |
| MeSH ID | M0103030 |
| Synonym |
|---|
| einecs 224-887-0 |
| 2,3-epoxypropiononitrile |
| ccris 6496 |
| 2-cyanoethylene oxide |
| glycidonitrile |
| cyanoethylene oxide |
| oxirane carbonitrile |
| brn 0103951 |
| glycidic acid nitrile |
| cyanooxirane |
| oxirane-2-carbonitrile |
| FT-0665284 |
| 4538-51-6 |
| unii-0c17iz13qv |
| 0c17iz13qv , |
| 5-18-06-00004 (beilstein handbook reference) |
| 2-acrylonitrile oxide |
| DTXSID10963379 |
| Q27236592 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " An exploratory study was conducted by using rat brain tumor data for acrylonitrile (AN) to investigate the use of physiologically based pharmacokinetic (PBPK) modeling along with pooling of dose-response data across routes of exposure as a means for improving carcinogen risk assessment methods." | ( Improving cancer dose-response characterization by using physiologically based pharmacokinetic modeling: an analysis of pooled data for acrylonitrile-induced brain tumors to assess cancer potency in the rat. Gargas, ML; Hays, SM; Kedderis, GL; Kirman, CR; Strother, DE, 2000) | 0.31 |
| "A physiologically based pharmacokinetic (PBPK) model of acrylonitrile (ACN) and cyanoethylene oxide (CEO) disposition in humans was developed and is based on human in vitro data and scaling from a rat model (G." | ( Physiologically based pharmacokinetic model parameter estimation and sensitivity and variability analyses for acrylonitrile disposition in humans. Gargas, ML; Kedderis, GL; Strother, DE; Sweeney, LM, 2003) | 0.32 |
| Excerpt | Relevance | Reference |
|---|---|---|
| ", N-acetyl-S-(1-cyano-2-hydroxyethyl)-L-cysteine (CHEMA) and N-acetyl-S-(2-hydroxyethyl)-L-cysteine (HEMA), were isolated from the urine of rats dosed with four successive doses of oxiranecarbonitrile (glycidonitrile, GN), 5 mg/kg, a reactive metabolic intermediate of acrylonitrile (AN)." | ( N-acetyl-S-(1-cyano-2-hydroxyethyl)-L-cysteine, a new urinary metabolite of acrylonitrile and oxiranecarbonitrile. Linhart, I; Novák, J; Smejkal, J, 1988) | 0.27 |
| " The pharmacokinetic data were well simulated, although CEO blood concentrations after bolus oral dosing were somewhat overestimated." | ( Refinement and verification of the physiologically based dosimetry description for acrylonitrile in rats. Batra, R; Gargas, ML; Held, SD; Kedderis, GL; Teo, SK, 1996) | 0.29 |
| " Environmental Protection Agency (EPA) guidelines for cancer risk assessment have acknowledged the value of better use of mechanistic data and better dose-response characterization." | ( Improving cancer dose-response characterization by using physiologically based pharmacokinetic modeling: an analysis of pooled data for acrylonitrile-induced brain tumors to assess cancer potency in the rat. Gargas, ML; Hays, SM; Kedderis, GL; Kirman, CR; Strother, DE, 2000) | 0.31 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 8 (27.59) | 18.7374 |
| 1990's | 15 (51.72) | 18.2507 |
| 2000's | 2 (6.90) | 29.6817 |
| 2010's | 3 (10.34) | 24.3611 |
| 2020's | 1 (3.45) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.62) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 31 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||